We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App

New, Highly Accurate, POC Test Measures Level of Neutralizing Antibodies (NAb) to COVID-19, Including Variants

By LabMedica International staff writers
Posted on 22 Dec 2021
Print article
Image: A prototype of the test (Photo courtesy of Burnet Institute)
Image: A prototype of the test (Photo courtesy of Burnet Institute)

A new, highly accurate, point-of-care (POC) test can measure the level of neutralizing antibodies (NAb) to COVID-19, including variants.

The test, developed by scientists at the Burnet Institute (Melbourne, Australia) and the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia), provides a readout from a fingerprick of blood in less than 20 minutes. The test is the first of its type globally, and could also be useful to indicate when a vaccine booster may be required. While there are many POC tests that can measure the overall level of antibody to SARS-CoV-2, and use this to estimate neutralizing antibodies, this is the only test to measure neutralizing antibody activity, which correlates with immune protection from serious disease in COVID-19.

The emergence of the Omicron variant, which early studies suggest may be up to 40-times less sensitive to patient NAb than Delta, means that some people will go from having enough NAb to be protected, to not having enough. The test provides a new option for immunity screening to support COVID-19 vaccination and control programs, particularly in time-critical and low- and middle-income settings where laboratory-based testing is difficult or impossible for many to access.

“One of the key elements of the test is that it can work with fingerprick whole blood, which is essential if it is really going to be used at point-of-care,” said study joint supervising author, Associate Professor David Anderson, Burnet Institute Deputy Director and Chief Scientific Officer of the Burnet Diagnostics Initiative.

“We envisage that this test may be part of a set of indications that will help to determine who may need a booster vaccine,” said Dr. Tom Fulford from the Doherty Institute. “This can also be adapted so that it can provide information about whether an individual has protective antibodies against particular variants of concern.”

Related Links:
Burnet Institute 
Doherty Institute 

Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Colloidal Gold)
Electrolyte Analyzer
3-Part Diff Hematology Analyzer
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.